Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret? -- Ignore unavailable to you. Want to Upgrade?

To: Stephen How who wrote (794)	3/31/1998 12:21:00 PM
From: Jim Roof	Read Replies (1) \| Respond to of 1432

<<In other words, the non-SS lower amounts of transfused products (platelets, RBC, etc) in the Hextend group resulted in a lower post-op platelet count -- a wash. >> I think this is an area of confusion. I view the post-op platelet count of Hextend patients (which is lower) as a positive in and of itself. This signifies to me that these patients were functioning just fine and clotting just fine without the need to boost the count via blood products. The lower use of platelets et al. is the direct reason for the lower platelet count but the underlying cause is that the Hextend patients performed as well with lower numbers (platelets and RBC) as the hetastarch patients did with transfused products as a supplement. I do not think it is accurate to view the lower post-op platelet and RBC as a negative. The bottom line is that the Hextend patients functioned well with higher concentrations of expander in their bloodstream. This is the marketing endpoint for Biotime. Less need for whole blood and safer performance of the fluid itself. I also find it noteworthy that the hetastarch patients had 8 incidents of major complication associated with the generic while the Hextend patients suffered only 2. These incidents were flagged before unblinding. Jim